Novo Nordisk A/S
NVOHealthcareNASDAQDrug Manufacturers - General · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Novo Nordisk A/S (NVO) is listed under Drug Manufacturers - General. At a $199.56B market cap, Novo Nordisk A/S ranks as a large-cap company within healthcare. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Market Cap
$199.56B
Beta
0.34
P/E (TTM)
11.10
P/E (Fwd)
13.21
EPS (TTM)
$4.07
EPS (Fwd)
$3.42
ROE
59.8%
ROA
18.7%
Cash
$44.98B
Total Debt
$140.13B
Free CF
$37.67B
52W Change
-14.3%
Annual Financials
Cash vs Debt
Where NVO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NVO finished 7.81% above its 150-day moving average ($43.38) and 3.82% above its 200-day moving average ($45.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVO overbought or oversold?
At the September 3, 2026 close, NVO's RSI(14) was 52.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, NVO has $44.98B in cash with $140.13B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $37.67B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 59.8%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 18.7% further supports the picture of efficient asset utilization. Revenue has grown from $176.95B (2022) to $309.06B (2025), reflecting a 75% increase over the period.
The relatively low beta of 0.34 suggests NVO is a less volatile holding compared to the broader index. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Novo Nordisk A/S's trajectory.